Clinical observation experience of a pediatric patient with primary progressive multiple sclerosis in the moscow office for the treatment of children and adolescents with multiple sclerosis

Objective. To demonstrate the experience of a personalized approach to the treatment of pediatric patients with multiple sclerosis using the example of the Moscow patient population. Materials and methods. The authors describe the clinical follow-up of 79 pediatric patients with demyelinating diseases of the nervous system during 2019, including 39 patients with multiple sclerosis, including one patient with a primary progressive course of the disease (clinical case). Results. The experience of the Moscow office for the treatment of multiple sclerosis in children and adolescents demonstrates the effectiveness of the personalized approach to the treatment of pediatric cases confirmed by the case report of biological therapy by recombinant humanized monoclonal antibody directed against CD20-expressing B-cells for early treatment of the adolescent patient with primary progressive multiple sclerosis. Conclusion. The identification of patient’s groups with different levels of disease activity and different risks of disability progres-sion is highly relevant in the pediatric population of patients with multiple sclerosis, especially in the context of expanding therapeutic opportunities. © 2020, Media Sphera Publishing Group. All rights reserved.

Authors
Bykova O.V. 1, 2 , Klimov Y.A. 1, 2 , Tikhonov S.V. 1, 2 , Lalabekova M.V. 1, 2 , Boyko E.A.1 , Batysheva T.T. 1, 2 , Boyko A.N.1, 3, 4
Number of issue
10
Language
Russian
Pages
45-50
Status
Published
Volume
120
Year
2020
Organizations
  • 1 Research and Clinical Centre of Pediatric Psychoneurology Moscow, Department of Public Health, Moscow, Russian Federation
  • 2 Medical Institute of the Peoples' Friendship University of Russia, Moscow, Russian Federation
  • 3 Pirogov Russian National Research Medical University, Moscow, Russian Federation
  • 4 Federal Center of Brain and Neurotechnologies, Moscow, Russian Federation
Keywords
Active multiple sclerosis; Clinically isolated syndrome; Disease modifying treatment (DMT); Monoclonal antibody; Pediatric multiple sclerosis; Primary progressive course
Date of creation
20.04.2021
Date of change
20.04.2021
Short link
https://repository.rudn.ru/en/records/article/record/72845/
Share

Other records